Seres Therapeutics CEO Roger Pomerantz taking advantage of a pre-event photo op.
What rain? Attendees filled up the Novartis Institutes for Biomedical Research despite some shaky weather.
The crowd settles in as Foundation Medicine CEO Mike Pellini (left) and Third Rock Ventures partner Alexis Borisy (right) give an inside look at the origins of Foundation.
Pellini and Borisy noted that there were often heated debates early on in the boardroom about Foundation's identity, and exactly how to build the company.
Jose-Carlos Gutierrez-Ramos left Pfizer to join a synthetic biology/microbiome hybrid startup called Synlogic. He explained the potential of the "living therapeutics" Synlogic is making, as well as the challenges that lie ahead.
Synlogic was spun out of the lab of MIT professor Jim Collins (left), who explained that the company has gone in a direction---rare metabolic disorders---that he didn't first envision. Gutierrez-Ramos (right) elaborated on the thinking behind that strategy.
An attendee checks in with a question for Collins and Gutierrez-Ramos.
Flagship Ventures CEO Noubar Afeyan, atypically wearing a suit, quipped: “Everybody’s been predicting the death of the IPO window for awhile, so I thought this would be the wake.”
Make sure to pay attention; we always set aside time for audience Q&A.
Pomerantz wasn't sold on any of Seres's CEO candidates, so as its chairman, he "pulled a Dick Cheney" and hired himself.
A guest explains how he came to acquire the coolest sweater in the house.
On Friday, I gave you all a recap of our latest biotech event, “Boston’s Life Science Disruptors.” As promised, today I’m circling back with some of the photos. As you’ll see, last week’s Boston monsoon cleared up just in time for the party.
Thanks again to our sponsors—BDO, Boston Children’s Hospital, Johnson & Johnson Innovation, New England Lab, and The Richmond Group—and to our speakers and event host Novartis. And of course a thanks to Keith Spiro of Keith Spiro Photography for all the shots you’ll see here. Catch you all in Boston again next time.
Ben Fidler is Xconomy's Deputy Editor, Biotechnology. You can e-mail him at firstname.lastname@example.org Follow @benthefidler
© 2007-2019, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.